NCT07340814

Brief Summary

This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
176mo left

Started Feb 2026

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
Feb 2026Oct 2040

First Submitted

Initial submission to the registry

January 6, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 14, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

February 27, 2026

Completed
14.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2040

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 15, 2040

Last Updated

January 14, 2026

Status Verified

January 1, 2026

Enrollment Period

14.6 years

First QC Date

January 6, 2026

Last Update Submit

January 6, 2026

Conditions

Any Patient Treated With MB-105

Outcome Measures

Primary Outcomes (1)

  • Assess long term safety of MB-105 in patients who received MB-105

    SAEs

    15 Years

Secondary Outcomes (1)

  • Assess long term efficacy of MB-105 in patients who received MB-105

    15 Years

Study Arms (1)

Open Observation

All patients who previously received MB-105 on another study

Biological: MB-105

Interventions

MB-105BIOLOGICAL

This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study

Open Observation

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who previously received MB-105 and consent to participate

You may qualify if:

  • Received MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements

You may not qualify if:

  • N/A

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 6, 2026

First Posted

January 14, 2026

Study Start

February 27, 2026

Primary Completion (Estimated)

October 15, 2040

Study Completion (Estimated)

October 15, 2040

Last Updated

January 14, 2026

Record last verified: 2026-01